Clik here to view.
Surgeon General Issues Call to Action on VTE: 23andMe Assesses Genetic Risk...
This Monday acting Surgeon General Steven K. Galson issued a Call to Action to reduce the number of people in the United States affected by two serious blood clotting conditions: deep vein thrombosis...
View ArticleClik here to view.
More Evidence that Genetics Can Reduce the Efficacy of Anti-Clotting...
A new report in the Journal of the American Medical Association adds to the mounting evidence that genetic variations impact the efficacy of clopidogrel (Plavix®), a drug used to prevent blood clots...
View ArticleClik here to view.
Medco to Include Genetics in Comparison of Anti-Clotting Drug Effectiveness
Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective...
View ArticleClik here to view.
Surgeon General Issues Call to Action on VTE: 23andMe Assesses Genetic Risk...
This Monday acting Surgeon General Steven K. Galson issued a Call to Action to reduce the number of people in the United States affected by two serious blood clotting conditions: deep vein thrombosis...
View ArticleClik here to view.
More Evidence that Genetics Can Reduce the Efficacy of Anti-Clotting...
A new report in the Journal of the American Medical Association adds to the mounting evidence that genetic variations impact the efficacy of clopidogrel (Plavix ®), a drug used to prevent blood clots...
View ArticleClik here to view.
Medco to Include Genetics in Comparison of Anti-Clotting Drug Effectiveness
Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix ®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective...
View Article
